SEC Form 4 · accession 0001209191-16-098331
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geert Cauwenbergh
Officer — President & CEO · Director
Period of report
Feb 10, 2016
Accepted (ET)
Feb 12, 2016 · 8:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $0.2858 | Feb 10, 2016 | A | 133,000 | A | — | Feb 10, 2026 | Common stock | 133,000 | 133,000 | D |
Explanation of responses
- F1The stock option vests in a one-quarter installment on the one year anniversary of the grant date and in monthly installments thereafter over the remaining three years.